The short version of prothymosin alpha fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-01. Anything still debated is marked as such rather than presented as settled.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
All craniate species have a distinct skull. However, not all of them possess vertebrae. The notochord is accompanied or replaced by the vertebral column in most craniates. Which consists of a series of cylindrical, and bony or cartilaginous vertebrae and projections that link the vertebrae. And these generally have neural arches that protect the spinal cord. Hagfish have incomplete braincases and lack vertebrae. Thus, they were regarded as non-vertebrate craniates. However, the cladistic exclusion of hagfish from the vertebrates is controversial, as they may have secondarily lost their vertebral columns, making them vertebrates. Molecular phylogenetics, which uses DNA sequences to classify organisms, has generally supported the grouping of hagfish and lampreys (which have vertebrae) in a clade named Cyclostomata, suggesting that the hagfish are indeed vertebrates. Examination of fossil hagfish also supports this conclusion. Indicating that Vertebrata is the same group as Craniata, instead of the former being a subset of the latter.
=== Allies === Wolverine is primarily presented as part of the X-Men and has had extensive interactions with all of them and their associates. Nightcrawler is one of his closest friends and was one of the first X-Men to look past Logan's demeanor, which was initially quite abrasive. Wolverine has also teamed up with Gambit on missions separate from the rest of the X-Men. In particular, Wolverine has a complex and ambivalent relationship with Cyclops, with whom he was initially a rival for the affections of Jean Grey. Logan was one of the original member of Alpha Flight, although he left the group out of frustration with their role as Canadian government operatives. He has also been a member of the Avengers, X-Force, and at times has joined the Fantastic Four. Outside his team allegiances, he has frequently allied with Elektra, particularly during periods when it becomes necessary for him to regain control of his impulses.
Measuring gene expression is an important part of many life sciences, as the ability to quantify the level at which a particular gene is expressed within a cell, tissue or organism can provide a lot of valuable information. For example, measuring gene expression can:
Nucleolus Nuclear speckle Cajal body Paraspeckle Synaptonemal complex Other nuclear structures including heterochromatin form by mechanisms similar to phase separation, so can also be classified as biomolecular condensates. RNAs with triplet expansion that produce neurodegenerative disorders can also independently form RNA foci in vitro or in mammalian nuclei. This phenomenon is further reconsituted in bacteria E. coli, by expressing engineered CAG repeats, providing strong evidence that these RNA repeats phase separate without the need of additional proteins.
Narrated by Tim Pigott-Smith, produced by Patrick Uden, directed by Sheila Hayman, made by Uden Associates 4 September The Tin Snail, about the Citroën 2CV; the 2CV was first introduced in October 1948; André Citroën saw himself as a French Henry Ford, and met American automotive industrialists in October 1931, including Henry Ford at the newly opened Ford Engineering Laboratory; the industrial historian Patrick Fridenson; Citroën lit up the Eiffel Tower in Citroën regalia, for publicity; but although André Citroën followed and admired Henry Ford, Citroën were innovative themselves, on 18 April 1934 the company launched the world's first mass-produced front-wheel drive car, the Citroën Traction Avant, when the company was narrowly avoiding bankruptcy; André Citroën died in 1935 and his company, being heavily in debt, was taken over by Édouard Michelin (brother of André Michelin); Fiat introduced its similar Fiat 500 in 1935, designed by Dante Giacosa; Ferdinand Porsche designed a new mass-produced car with rear air-cooled horizontally-opposed four-cylinder engine; France did not have such a car to Germany, so Citroën developed the Toute Petite Voiture (TPV), a proposal of Pierre Michelin - he brought in André Lefèbvre, who had designed the front-wheel-drive system of the Traction Avant and was a former aircraft engineer of Voisin, and led by Pierre-Jules Boulanger; Lefèbvre came from the aviation industry, and to save weight, made the car out of aluminium; the car had a torsion bar suspension, with eight torsion bars; Flaminio Bertoni, an Italian, was head of exterior design at Citroën, from 1932 to 1964; Carl Olsen, head of Citroën exterior design from 1982 to 1987; Alex Moulton, the Cambridge-educated mechanical engineer, who designed the suspension for the innovative Mini, in the late 1950s; Lucien Gerard, from Talbot, and Walter Becchia, who designed the two-cylinder water-cooled horizontally opposed engine. Narrated by Peter Jones, produced by Patrick Uden, directed by Jeremy Llewellyn-Jones, made by Uden Associates 11 September Deep Trouble, about the North Sea oil industry; the beginning of 1986 saw peak production of North Sea oil; finding new oil reserves would be from deeper oil fields, that cost more money to extract; at the same time the oil price plummeted, with over 15,000 job losses in the British oil industry by the end of 1986; Vickers Ltd entered the oil exploration industry; submersible craft were helping exploration of oil, with remotely operated craft becoming important. Narrated by Martin Jarvis, produced by Patrick Uden, directed by Paul Fabricius, made by Uden Associates 18 September What They Don't Tell You When They Sell You a Computer, about professionalism in the computer hardware industry; Eddy Shah from the Today newspaper, and their new unreliable computer system; Brian Wilson of First Computer believed that the computer hardware retailing industry were largely unprofessional unscrupulous cowboys; the National Computing Centre (NCC) was set up by the government in 1966, to provide advice; BP opened its own Microshop, to circumvent the cowboys, and assist with technical jargon, and connecting devices; due to warp-drive technical obsolescence in the 1980s, yesterday's computers rapidly lost all total value; Iain Callaghan, operations director of John Menzies newspaper distribution business, and how computer databases could process newsagents' daily orders much quicker and reliably; Geoff Dalby, head of data at Woolwich Equitable Building Society, which had called off a merger with the Nationwide Building Society, as their computer systems would not work together; greater computer automation of the personal finance industry could lead to much less day-to-day contact with individual customers; David Bailey of Phillips & Drew. Narrated by Miriam Margolyes, produced by Michael Blakstad, directed by Catherine Robins, made by Workhouse Productions 25 September Precisely in Profit, about manufacturing to exact margins. Produced by Glyn Jones, directed by Eben Wilson, made by Quanta 2 October Now Eat This, about snack foods. Produced by Edward Poulter, directed by Mike Tomlinson, made by London Scientific Films 9 October Growing up with Rockets, a personal, and underreported, view of early elementary rocketry from 1950, starting with captured German V-2 rockets; the former 1970 class of Cocoa Beach High School; failed launches would land in the Banana River; NASA was formed in July 1958, in a coherent response to the Russian launches in 1957; the President visits Cocoa Beach to celebrate the US getting a man to orbit the Earth in February 1962; the nearby Patrick Air Force Base; Syncom 3 was launched on 19 August 1964, the world's first geostationary communication satellite, on a Delta rocket; the minutes leading up to the first launch of STS-1 in April 1981. Directed and a first hand account of Nancy Yasecko, produced by Patrick Uden, made by Uden Associates 16 October Shock Trauma, about the Baltimore Shock Trauma Center (R Adams Cowley Shock Trauma Center). A Canadian production, produced by Patrick Uden, made by National Film Board of Canada and Uden Associates 23 October Drink Drive and Murder; it featured two court cases in the US, where a 33 year old killed a couple in their 20s, and a 17 year old who killed a couple of teenagers, and a Californian drink-drive reform centre; in some US states, if you kill when drunk, the charge is murder. A Canadian production, made by Uden Associates and the National Film Board of Canada 30 October The New Magicians, about film special effects; Gertie the Dinosaur in 1914 and The Sinking of the Lusitania in 1918; the King Kong (1933 film); the 1950s and 1960s saw modest increases in special effects, notably Forbidden Planet in 1956, until 2001: A Space Odyssey was important in 1968; another important film was Star Wars (film) in 1977, along with Close Encounters of the Third Kind, Tron in 1982 and The Last Starfighter in 1984. A Canadian production, produced by Ken McKay, made by TV Ontario 6 November Pioneers of the Future, about the development of microchips, such as Steve Dorsey, who invented the word processor. A Canadian production, produced by Ken McKay, made by Uden Associates and TV Ontario 13 November Skyscraper, about Old Madison Square Gardens and skyscrapers in Chicago and New York; Arthur Nusbaum; architect Stanley Tigerman; the tallest masonry-only building was 16 storeys high; the Great Chicago Fire in October 1871, which allowed different, and stronger, structures of building to be built instead; the 1902 Flatiron Building; architect Jack Hartray; mechanical engineer George Strakosch; the 1908 600-feet Singer Building; the 1912 800-feet Woolworth Building; the 1915 Equitable Building (Manhattan); the 1930 900-feet Chrysler Building; the 1931 1250-feet Empire State Building; mechanical engineer David Stillman; structural engineer Charles Thornton; architect Robert Sobel; structural engineer Leslie E. Robertson; civil engineer Alan Garnett Davenport of the University of Western Ontario; architect Bruce Graham; architect Harry Weese; architect Moshe Safdie. Narrated by William Woollard, produced by Nicola Glucksmann, directed by Karl Sabbagh, made by InCA
Sources: en.wikipedia.org
== Personal life == Woolley married bacteriologist Janet Ruth McCarter in 1945. Woolley had Diabetes mellitus type 1 from childhood, and in 1923 was among the first children to receive insulin to treat the condition. He nonetheless experienced blindness as a complication of his diabetes, and was completely blind from age 25 until his death from a heart attack at age 52, while hiking in Cuzco, Peru.
==== Non-synthesizers ==== Some mammals have lost the ability to synthesize vitamin C, including simians and tarsiers, which together make up one of two major primate suborders, Haplorhini. This group includes humans. The other more primitive primates (Strepsirrhini) have the ability to make vitamin C. Synthesis does not occur in some species in the rodent family Caviidae, which includes guinea pigs and capybaras, but does occur in other rodents, including rats and mice. Synthesis does not occur in most bat species, but there are at least two species, frugivorous bat Rousettus leschenaultii and insectivorous bat Hipposideros armiger, that retain (or regained) their ability of vitamin C production. A number of species of passerine birds also do not synthesize, but not all of them, and those that do not are not clearly related; it has been proposed that the ability was lost separately a number of times in birds. In particular, the ability to synthesize vitamin C is presumed to have been lost and then later re-acquired in at least two cases. The ability to synthesize vitamin C has also been lost in about 96% of extant fish (the teleosts). Schistosomes (parasitic flatworms) cannot synthesize vitamin C and require it from their hosts in order to produce eggs; in both guinea pigs and in mice genetically engineered to be non-synthesizers, vitamin C deficiency prevents schistosomes from reproducing. In mice, it has additionally been found that vitamin C deficiency (even intermittent) prevents schistosomes from causing disease.
Ring or Double arcuate scotoma: Two arcuate scotomas join to form a Ring or Double arcuate scotoma. This defect is seen in advanced stages of glaucoma. Roenne's central nasal step: It is created when two arcuate scotomas run in different arcs to form a right-angled defect. This is also seen in advanced stages of glaucoma. Peripheral field defects: Peripheral field defects may occur in early or late stages of glaucoma. Roenne's peripheral nasal steps occur due to contraction of peripheral isopter. Tubular vision: Since macular fibers are the most resistant to glaucomatous damage, the central vision remains unaffected until the end stages of glaucoma. Tubular vision or Tunnel vision is the loss of peripheral vision with retention of central vision, resulting in a constricted circular tunnel-like field of vision. It is seen in the end stages of glaucoma. Retinitis pigmentosa is another disease that causes tubular vision. Temporal island of vision: It is also seen in the end stages of glaucoma. The temporal islands lie outside of the central 24 to 30° visual field, so it may not be visible with standard central field measurements done in glaucoma.
=== Animal glutamate–cysteine ligase === Animal glutamate cysteine ligase (GCL) is a heterodimeric enzyme composed of two protein subunits that are coded by independent genes located on separate chromosomes:
Sources: en.wikipedia.org
{\displaystyle P(t)=e^{Qt}={\begin{pmatrix}p_{\mathrm {AA} }(t)&p_{\mathrm {AC} }(t)&p_{\mathrm {AG} }(t)&p_{\mathrm {AT} }(t)\\p_{\mathrm {CA} }(t)&p_{\mathrm {CC} }(t)&p_{\mathrm {CG} }(t)&p_{\mathrm {CT} }(t)\\p_{\mathrm {GA} }(t)&p_{\mathrm {GC} }(t)&p_{\mathrm {GG} }(t)&p_{\mathrm {GT} }(t)\\p_{\mathrm {TA} }(t)&p_{\mathrm {TC} }(t)&p_{\mathrm {TG} }(t)&p_{\mathrm {TT} }(t)\end{pmatrix}}}
On 13 September 1945, a Franco-British task force landed in Java, main island of the Dutch East Indies (for which independence was being sought by Sukarno), and Saigon, capital of Cochinchina (southern part of French Indochina), both being occupied by the Japanese under Field Marshal Hisaichi Terauchi, Commander-in-Chief of Japan's Southern Expeditionary Army Group based in Saigon. Allied troops in Saigon were an airborne detachment, two British companies of the Indian 20th Infantry Division and the French 5th Colonial Infantry Regiment, with British General Sir Douglas Gracey as supreme commander. The latter proclaimed martial law on September 21, and Franco-British troops took control of Saigon.
p53, also known as tumor protein p53, TP53, cellular tumor antigen p53 (UniProt name), or transformation-related protein 53 (TRP53) is a regulatory transcription factor protein that is often mutated in human cancers. The p53 proteins (originally thought to be, and often spoken of as, a single protein) are crucial in vertebrates, where they prevent cancer formation. As such, p53 has been described as "the guardian of the genome" because of its role in conserving stability by preventing genome mutation. Hence TP53 is classified as a tumor suppressor gene. The TP53 gene is inactivated in a majority (>50%) of human cancer cases. This can be caused by any various factors, including mutations in the gene, epigenetic events, or interactions with other proteins. This association indicates that the TP53 gene plays a crucial role in preventing cancer formation. TP53 gene encodes proteins that bind to DNA and regulate gene expression to prevent mutations of the genome. In addition to the full-length protein, the human TP53 gene encodes at least 12 protein isoforms. Comparative genomic studies found pathogenic mutations absent in some Neanderthal populations, while modern humans exhibit an expansion of over 1,000 mutated variations. Evidence suggests that the vast majority of these protein-coding variants arose very recently in human history, specifically concentrated within a window of 5,000 to 10,000 years ago.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.